Related Experiment Videos
An experimental meningitis with Streptococcus pneumoniae in rats: therapeutic effect of aspoxicillin and its
T Yamaguchi1, O Kasuga, S Okuno
1Biological Research Laboratory, Tanabe Seiyaku Co. Ltd., Saitama, Japan.
Abstract:
An experimental meningitis model was produced in rats with Streptococcus pneumoniae Type III and used to evaluate the therapeutic effect of aspoxicillin in comparison with piperacillin, mezlocillin and ampicillin. At the same time, their bactericidal activities and pharmacokinetics in cerebrospinal fluid (CSF) were determined. The experimental meningitis model was prepared by intracisternal inoculation of the organism. The rats in this model began to die 2 days after the infection and all died within 5 days. Histological examination also revealed that this model was a fatal pneumococcal meningitis model in rats. The concentrations of these penicillins in CSF of the infected rats determined by the high performance liquid chromatography method were significantly increased by bacterial infection. Of these drugs, ASPC gave the highest penetration into the infected CSF and the longest persistency in CSF. In a comparison of the bactericidal activity of these penicillins in this model, aspoxicillin at a dose of 20 mg/kg inhibited the regrowth of bacteria in CSF 24 h after administration, but the other three penicillins did not. To conclude, in this new experimental meningitis model in rats, aspoxicillin showed an excellent therapeutic effect due to its stronger bactericidal action and favourable pharmacokinetic properties.
Insights
Aspoxicillin demonstrated superior efficacy in a rat meningitis model caused by Streptococcus pneumoniae. This antibiotic offered better cerebrospinal fluid penetration and bactericidal activity compared to other penicillins, indicating excellent therapeutic potential.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Bacterial meningitis, particularly pneumococcal meningitis, remains a significant global health challenge.
- Effective antibiotic treatment requires drugs with optimal penetration into the cerebrospinal fluid (CSF) and potent bactericidal activity.
- Existing penicillin therapies may have limitations in treating severe bacterial meningitis.
Purpose of the Study:
- To evaluate the therapeutic efficacy of aspoxicillin against Streptococcus pneumoniae meningitis in a rat model.
- To compare aspoxicillin's pharmacokinetic properties and bactericidal activity in CSF with piperacillin, mezlocillin, and ampicillin.
- To establish a reliable experimental model for studying pneumococcal meningitis treatment.
Main Methods:
- An experimental meningitis model was established in rats using intracisternal inoculation of Streptococcus pneumoniae Type III.
- Therapeutic effects of aspoxicillin, piperacillin, mezlocillin, and ampicillin were assessed.
- Bactericidal activity and CSF pharmacokinetics of the penicillins were determined using high-performance liquid chromatography (HPLC).
Main Results:
- The rat model successfully replicated fatal pneumococcal meningitis, with high mortality rates within 5 days.
- Bacterial infection significantly increased penicillin concentrations in the CSF.
- Aspoxicillin exhibited superior CSF penetration and longer persistence compared to the other tested penicillins.
- Aspoxicillin inhibited bacterial regrowth in CSF for 24 hours post-administration, unlike the other antibiotics.
Conclusions:
- Aspoxicillin demonstrated excellent therapeutic effects in this novel experimental meningitis model.
- Its superior performance is attributed to enhanced bactericidal action and favorable pharmacokinetic properties, including better CSF penetration and sustained levels.
- Aspoxicillin represents a promising therapeutic agent for treating pneumococcal meningitis.